Without Measles Herd Immunity, Vulnerable Kids Are at Risk
In this segment, Dr Jacobson discusses the importance of vaccine efficacy in controlling measles outbreaks. The measles vaccine is 97% effective, meaning a small percentage of individuals do not develop immunity. Herd immunity protects these individuals by limiting the virus's ability to spread. Dropping vaccination rates, now at 92% for kindergarteners, leaves those who do not respond to the vaccine at increased risk. Dr Offit references a 1999 measles outbreak in the Netherlands, where vaccinated individuals in largely unvaccinated communities faced greater risk than unvaccinated individuals in communities with high vaccination coverage.
Key Takeaways:
The vaccine is 97% effective, leaving a small portion of individuals without immunity.
Community-level vaccination rates matter: Exposure risk increases even for vaccinated individuals in areas with low overall coverage.
Herd immunity creates protective 'halos' around those who are vulnerable, highlighting the need to maintain high immunization rates.
To View Entire Event Recording:
WATCH NOW - Measles Resurgence: What Physicians Must Know Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Gilead's Yeztugo sales 'ahead of expectations' following launch
After Gilead Sciences was given the green light for Yeztugo (lenacapavir) in the US and Europe, CCO Johanna Mercier said it is 'well ahead of expectations' in a Q2 investor call. The twice-yearly pre-exposure prophylaxis (PrEP) therapy has made headlines for its capacity to prevent 100% of HIV cases in a trial involving South African and Ugandan women – resulting in the jab's approval in June. While Gilead did not reveal how much the flagship drug has made for the company thus far, Mercier noted that unaided awareness on Yeztugo was 'at about 72%,' which is 'more than double that you'd see in industry at launch'. Looking forward, GlobalData, parent company of Pharmaceutical Technology, has forecasted that the star HIV drug will bring in just under $5bn in 2031, making it one of the company's most lucrative assets. However, some analysts had concerns about the drug's future uptake following the Supreme Court's ruling to allow Robert F. Kennedy Jr. (RFK Jr.) free rein over the US Preventive Services Task Force's (USPSTF) staffing and decision-making. Though the USPSTF currently recommends the use of Yeztugo as a preventive therapy for HIV, analysts feared that the division's restructure or complete overhaul could impact guidelines around the PrEP's usage, though Mercier believes that Gilead could 'work through it' by collaborating closely with its payers if this were to occur. The World Health Organisation (WHO) also recently announced new guidelines, which shift the agency's focus to preventive treatments, while prioritising the lowering of barriers to patient care for HIV management. Gilead has pledged to allow affordable Yeztugo in low-and middle-income countries after UNAIDS' executive director, Winnie Byanyima, called upon Gilead to allow for the immediate production of Yeztugo generics, as the drug's $40k US price tag could leave many in lower-income countries unable to afford treatment. HIV portfolio drives Gilead's overall growth On top of the early-stage success enjoyed by Yeztugo, Gilead has reported positive results for its HIV portfolio as a whole, with sales in this indication totalling $4.15bn this quarter. Blockbuster antiretroviral Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) also had 'one of its best quarters ever,' with sales jumping 9% to $3.5bn – constituting nearly half of the pharma's overall profits in the second quarter. Though the drug's patent is set to expire in October 2027, GlobalData's infectious disease analyst Anaelle Tannen noted that no HIV therapy is likely to be superior to Biktarvy in terms of commercial success. This is supported by GlobalData's forecast of a sales drop for Biktarvy's main competitor Dovato (dolutegravir and lamivudine), produced by ViiV Healthcare, which GlobalData forecasts will drop from $3.4bn in 2027 to $1.6bn in 2031, in part due to patents likely being made available in 2031. Though the HIV market is highly lucrative, with GlobalData predicting the HIV market will surpass $32bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). There are more than 40 drugs now approved for use in the indication, meaning pharma companies will have to differentiate themselves substantially to get a slice of this crowded market. One way companies are trying to differentiate is through the development of an HIV vaccine. While none have yet shown great promise, with two trials by Scripps Research, IAVI and additional collaborators across the US and Africa showing proof of concept at Phase I. "Gilead's Yeztugo sales 'ahead of expectations' following launch" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Ham and bacon sold in Tesco and M&S found to contain cancer-causing chemicals
Ham and bacon sold in UK supermarkets still contain cancer-causing chemicals almost 10 years after the World Health Organisation (WHO) warned about the dangers of using it in processed meats. Supermarkets including Tesco and Marks & Spenser have been found to sell meats containing nitrite, according to a recent study that found all 21 products tested in a laboratory contained the chemical. Wiltshire ham was found to have the highest concentrations of nitrites, according to analysis that compared it to cooked ham and unsmoked bacon. Almost 33 milligrams of nitrites per kilogram was found in Tesco's Wiltshire ham. That's 11 times that amount in its cooked ham (2.88mg/kg) and almost four times the in its unsmoked bacon (8.64mg/kg). It was also almost 18 times the found in Morrisons's bacon (1.84mg/kg). Wiltshire ham products sold by M&S contained 28.6 mg/kg, at Sainsbury's 21.1mg/kg and Morrisons 19.2mg/kg - which are all considered to be high levels. But at Asda the Wiltshire ham contained lower levels at 8mg/kg. However, the analysis, commissioned by the Coalition Against Nitrites and undertaken by Food Science Fusion and the laboratory experts Rejuvetech, found the levels of nitrites in all 21 products were well below the 150mg/kg legal limit. Eating processed meat, such as ham, bacon and sausages which contain nitrites increases the risk of bowel cancer according to health experts. Cancer Research UK estimates about 13 per cent of the 44,100 cases of bowel cancer diagnosed each year in the UK are linked to eating processed meat. In 2015, the World Health Organisation classified processed meat as carcinogenic, based on the evidence that it causes cancer. Nitrites are a crucial ingredient in meat curing, they provide colour, flavour and prevent the growth of harmful bacteria. But there are now alternatives available that are less harmful. Ruth Dolby, Food Science Fusion Director, told the Independent: 'The levels of Nitrites are moving down, but they are not being 100 per cent removed.' 'Nitrites were originally used as the most effective preservatives from a food safety perspective. There are legal upper limits, but no legal lower limits. 'Food Science research and understanding has taken great leaps in the last 20 years, we now know that there are alternative, natural, equally effective ingredients that have less negative impact on the human body and the environment, especially the water courses.' Wiltshire ham in particular contains high levels of the chemical because during the productions process the pork is injected with nitrates and soaked in a bath of brine and nitrites. This gives it its red colour and prevent the growth of bacteria. At that point a chemical reaction occurs, which turns nitrates into nitrites. A spokesperson for the Coalition Against Nitrites, told the Guardian: 'It's nearly a full decade since the WHO classified nitrite-cured processed meats as a group one carcinogen, and it is disappointing and alarming that we continue to see products on sale containing high levels of nitrites.' They added: 'Consumers are increasingly aware of the dangers of nitrites in processed meats, yet they continue to be exposed to their risks.' Tesco's has said its Wiltshire ham contains levels of nitrites significantly lower than the legal limits allowed in the UK and EU. A Tesco spokesperson said: 'We follow all UK and EU requirements, alongside guidance from the UK Food Standards Agency, to ensure we get the right balance of improving the shelf life and safety of our products with limited use of additives. The nitrites levels in all of our products, including our traditionally cured Finest Wiltshire ham, fall significantly below the legal limits in the UK and EU. 'We work closely with our suppliers to make sure that all additives including nitrites are only used when necessary and we are committed to clear labelling for all our products so customers can check product ingredients lists to see which products contain additives such as nitrites. 'Nitrates and nitrites are an important part of the curing process for some meats and they are used to prevent the growth of harmful bacteria that cause serious food poisoning.' Andrew Opie, Director of Food and Sustainability at the BRC, said:'Food safety is paramount to our members and they implement strict policies with their suppliers to ensure all products comply with UK food legislation. Additives such as nitrites are controlled, and their use is regularly monitored by the food safety authorities' M&S, Sainsbury's and Asda have all been approached for a comment.
Yahoo
3 hours ago
- Yahoo
From Young to Senior: How to Support Rats and Mice Through All Life Stages
Whether lively young animals or calm seniors, the lives of rats and mice unfold in fast-forward. Because their lifespan is only a few years, it's important for owners to understand the different life stages. Those who want to optimally support their pets should know how behavior and needs change with age—and what matters for mice and rats in each life phase, according to an expert. Short Lifespan with Many Developmental Stages The lifespan of fancy mice is usually between one and a half to two years. Some individuals can live up to four years. Rats generally live a bit longer—between two and three years. Since their youth lasts only a few weeks, these animals make significant developmental strides quickly. Juvenile Phase—Discover, Learn, Grow 'The first weeks of life for rats and mice are rapid,' explains Dr. Barbara Schneider, a specialist veterinarian for behavioral science and a public health officer at the Bavarian State Office for Health and Food Safety (LGL), in a statement. 'During the second week of life, their eyes open, and by about three weeks, the young are weaned from their mother.' During this time, the animals begin to explore their environment, develop initial social skills, and form bonds with peers and humans. Many owners do not experience this life phase with mice and rats, as they are usually only given away once they reach sexual maturity. Mice typically reach sexual maturity at three to four weeks and are fully grown by six to eight weeks. For rats, it takes about two months to reach sexual maturity, and they achieve their final size at around four to five months. Also interesting: Can I extend the lifespan of my rats? Adolescence and Adulthood—Active and Eager to Learn 'From as early as six weeks, when they eat independently and are accustomed to self-determined life in a group, young adults can move to a new home. Especially in the first weeks, they benefit from regular, gentle contact with their human: This provides security and lays the foundation for how the animals will later respond to human contact,' says Dr. Schneider. 'Adulthood is also a good time to teach these intelligent animals tricks. It is simultaneously the most active phase. Here, the animals show their individual personalities and engage a lot with their peers.' During this time, it is particularly important to provide a species-appropriate and varied environment with several peers. Since rats and mice spend most of their time in their home, a cage or suitable enclosure, owners should ensure a stress-free life in this environment. This includes fixed routines, rest periods, and sufficient space with retreats, tubes, and climbing opportunities. Daily free-range time and various activity offerings also help prevent boredom and stress. Senior Phase—Needs Change Much changes with age. Mice show the first signs of aging at about one year, while rats usually do so around 18 months. 'Mobility gradually decreases, the fur may become thinner, and there is a greater need for sleep and rest,' explains expert Schneider. 'Many older animals remain active and curious—just at a slower pace.' To ensure older animals cope well, owners should adjust the environment accordingly. Sleeping and feeding areas should be easily accessible, and climbing levels should be lowered. Health checks should be conducted regularly during this life phase. Issues like weight loss or dental changes can be detected and treated early. An experienced veterinarian should regularly check older animals to identify any non-visible diseases. With attentive care and an adapted environment, rats and mice can lead a fulfilling and as long a life as possible—even beyond the statistical life expectancy. The post From Young to Senior: How to Support Rats and Mice Through All Life Stages appeared first on PETBOOK.
